IFM Investors Pty Ltd buys 30,190 shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA)


IFM Investors Pty Ltd increased its stake in Teva Pharmaceutical Industries Limited (NYSE: TEVAGet a rating) by 22.3% in the first quarter, HoldingsChannel reports. The company held 165,346 shares of the company after acquiring an additional 30,190 shares during the period. IFM Investors Pty Ltd’s holdings in Teva Pharmaceutical Industries were worth $1,553,000 when it last filed with the Securities and Exchange Commission.

Other big investors have also been buying and selling shares of the company recently. Fieldpoint Private Securities LLC increased its position in Teva Pharmaceutical Industries shares by 100,000.0% during the first quarter. Fieldpoint Private Securities LLC now owns 3,003 shares of the company valued at $28,000 after acquiring an additional 3,000 shares during the period. Koshinski Asset Management Inc. increased its position in Teva Pharmaceutical Industries shares by 61.6% during the fourth quarter. Koshinski Asset Management Inc. now owns 3,934 shares of the company valued at $32,000 after acquiring an additional 1,500 shares during the period. Kistler Tiffany Companies LLC increased its position in Teva Pharmaceutical Industries shares by 932.2% during the fourth quarter. Kistler Tiffany Companies LLC now owns 4,139 shares of the company valued at $33,000 after acquiring 3,738 additional shares during the period. Huntington National Bank increased its position in Teva Pharmaceutical Industries shares by 115.7% during the fourth quarter. National Bank Huntington now owns 4,850 shares of the company valued at $38,000 after acquiring an additional 2,601 shares during the period. Finally, Future Financial Wealth Management LLC purchased a new equity stake in Teva Pharmaceutical Industries during the 4th quarter at a value of $49,000. 45.79% of the shares are held by institutional investors and hedge funds.

Shares of TEVA Stock opened at $7.89 on Friday. The stock has a market capitalization of $8.71 billion, a P/E ratio of -14.35, a PEG ratio of 0.97 and a beta of 1.17. Teva Pharmaceutical Industries Limited has a 52-week low of $7.23 and a 52-week high of $10.50. The company has a quick ratio of 0.73, a current ratio of 1.07 and a debt ratio of 2.03. The company’s fifty-day simple moving average is $8.31 and its two-hundred-day simple moving average is $8.51.

Teva Pharmaceutical Industries (NYSE: TEVAGet a rating) last announced its quarterly results on Tuesday, May 3. The company reported EPS of $0.53 for the quarter, reaching the consensus estimate of $0.53. The company posted revenue of $3.66 billion for the quarter, versus $3.75 billion expected by analysts. Teva Pharmaceutical Industries recorded a negative net margin of 3.95% and a positive return on equity of 24.04%. The company’s quarterly revenue fell 8.1% from the same quarter last year. In the same quarter of the previous year, the company achieved EPS of $0.60. On average, analysts expect Teva Pharmaceutical Industries Limited to post an EPS of 2.39 for the current fiscal year.

A number of equity research analysts have recently released reports on TEVA shares. Bank of America downgraded shares of Teva Pharmaceutical Industries from an “underperforming” to a “neutral” rating and set a price target of $9.00 for the company in a Tuesday 17 research report. may. StockNews.com moved shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Friday, June 17. Sanford C. Bernstein upgraded shares of Teva Pharmaceutical Industries from a “market performance” rating to an “outperform” rating and set a target price of $11.00 for the company in a Friday 25 report. march. UBS Group assumed coverage of Teva Pharmaceutical Industries shares in a Monday, June 13 report. They issued a “neutral” rating and a target price of $10.00 for the company. Finally, Piper Sandler downgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and lowered her share price target from $11.00 to $7.00 in a Wednesday, May 4 report. One analyst rated the stock with a sell rating, five gave the company a hold rating and three gave the company a buy rating. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $10.71.

In other news from Teva Pharmaceutical Industries, Vice President Hafrun Fridriksdottir sold 130,000 shares of the company in a trade on Tuesday, May 17. The shares were sold at an average price of $8.22, for a total value of $1,068,600.00. Following the sale, the vice president now owns 1,387 shares of the company, valued at approximately $11,401.14. The sale was disclosed in a filing with the SEC, accessible via the SEC website. 0.82% of the shares are held by insiders.

About Teva Pharmaceutical Industries (Get a rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generic drugs, specialty drugs and biopharmaceuticals in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments and creams.

See also

Want to see which other hedge funds hold TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE: TEVAGet a rating).

Institutional ownership by quarter for Teva Pharmaceutical Industries (NYSE: TEVA)



Get news and reviews for Teva Pharmaceutical Industries Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily newsletter.